MYCN and neuroblastoma: The most common and most clearly implicated genomic alteration is the MYCN gene amplification, which is present in ~18% of cases, considering WGS or WES data of 1232 NB samples from two different studies combined with data generated by the Therapeutically Applicable Research to Generate Effective Treatment initiative (TARGET, https://ocg.cancer.gov/programs/target_phs000467 (accessed on 21 June 2021 via cBio Portal for Cancer Genomic https://www.cbioportal.org/)) [15,16].